Table 1. Studies of convalescent plasma therapy for treating COVID-19.

Authors, Year of publication	Country	Study design	Number of participants		Clinical outcomes		Adverse events	Reference
			Cases	Controls	Cases	Controls
Abolghasemi et al., 2020	Iran	Nonrandomized, controlled study	115	74	14.8% died	24.3% died	Not reported	[27]
Ahn et al., 2020	Korea	Nonrandomized, non-controlled study	2		100% improved		None	[23]
Duan et al., 2020	China	Nonrandomized, non-controlled study	10		100% improved within 3 days		1 evanescent facial red spot	[20]
Li et al., 2020	China	Randomized, controlled study	53	51	51.9% improved within 28 days	41.1% improved within 28 days	2 adverse events within hours after transfusion	[28]
Perotti et al., 2020	Italy	Nonrandomized, non-controlled study	46		6.5% died within 7 days		5 serious adverse events	[26]
Salazar et al., 2020	US	Nonrandomized, non-controlled study	25		76% improved within 14 days		None	[25]
Shen et al., 2020	China	Nonrandomized, non-controlled study	5		100% improved		None	[21]
Zeng et al., 2020	China	Nonrandomized, non-controlled study	6	15	83% died	93% died	None	[24]
Zhang et al., 2020	China	Nonrandomized, non-controlled study	4		100% improved		None	[22]

COVID-19, coronavirus disease 2019.